TD Cowen Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by TD Cowen from $1,020.00 to $1,030.00 in a report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on the stock. Truist Financial restated a buy rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an outperform rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an outperform rating in a research report on Monday, February 5th. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an outperform rating and a $1,125.00 price objective on the stock. Finally, Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a research report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $977.77.

Regeneron Pharmaceuticals Trading Down 0.8 %

NASDAQ REGN opened at $883.20 on Wednesday. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $998.33. The company has a 50-day simple moving average of $948.00 and a 200-day simple moving average of $893.63. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm has a market capitalization of $96.94 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the firm posted $10.96 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the stock. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.